Volume 16, Issue 56 (Jan 2007)                   J Mazandaran Univ Med Sci 2007, 16(56): 21-28 | Back to browse issues page

XML Persian Abstract Print


Abstract:   (14326 Views)
Background and purpose: Brucellosis is a major bacterial zoonosis of global importance. Effective host defence against brucella depends on immunoglobulin G-mediated phagocytosis of the bacteria and it has been shown that the FC RIIA polymorphism (FCγ RIIA-R131 vs FCγ RIIA –H131) determines the capacity of immunoglobulin G-mediated phagocytosis via this receptor. The aim of this study was to evaluate the FCγRIIA polymorphism in patients with brucellosis and to reveal any relation between this polymorphism and disease progression.
Materials and Methods: In this study we evaluated FCγRIIA polymorphisms (R/R131, R/H131, H/H131) in 67 patients with serologically proven brucellosis and 67 healthy volunteers matched for age, sex and geographical area. FCγRIIA polymorphism was determined using a polymerase chain reaction method (SSCP-PCR).
Results: The frequency of FCγ RIIA-R/R131 genotype was higher in patients with brucellosis compared with controls (47.8% vs 28.4%). This genotype has a (OR=2.1, 95%CI=1.3-4.2, P=0.039) significant correlation with brucellosis. However, no significant difference was found between patients with brucellosis and controls (P=0.2) Although the frequency of FCγRIIA-R/R131 was higher in patients with brucellosis compared with controls, we did not find any statistically significant differences (53.8% vs46.3%, P=0.2). As a result, there was no significant association between FCγRIIA genotype and severity of brucellosis.
Conclusion: Based on the results, the dominance of homozygous genotype of FCγRIIA-R/R131 in patients with bracellosis emphasize the importance of this predisposing genetic risk factor in contracting the disease.
Full-Text [PDF 289 kb]   (2435 Downloads)    
Type of Study: Research(Original) |

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.